Literature DB >> 25265485

Functional study of miR-27a in human hepatic stellate cells by proteomic analysis: comprehensive view and a role in myogenic tans-differentiation.

Yuhua Ji1, Jinsheng Zhang2, Wenwen Wang3, Juling Ji3.   

Abstract

We previous reported that miR-27a regulates lipid metabolism and cell proliferation during hepatic stellate cells (HSCs) activation. To further explore the biological function and underlying mechanisms of miR-27a in HSCs, global protein expression affected by overexpression of miR-27a in HSCs was analyzed by a cleavable isotope-coded affinity tags (cICAT) based comparative proteomic approach. In the present study, 1267 non-redundant proteins were identified with unique accession numbers (score ≥1.3, i.e. confidence ≥95%), among which 1171 were quantified and 149 proteins (12.72%) were differentially expressed with a differential expression ratio of 1.5. We found that up-regulated proteins by miR-27a mainly participate in cell proliferation and myogenesis, while down-regulated proteins were the key enzymes involved in de novo lipid synthesis. The expression of a group of six miR-27a regulated proteins was validated and the function of one miR-27a regulated protein was further validated. The results not only delineated the underlying mechanism of miR-27a in modulating fat metabolism and cell proliferation, but also revealed a novel role of miR-27a in promoting myogenic tans-differentiation during HSCs activation. This study also exemplified proteomics strategy as a powerful tool for the functional study of miRNA.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25265485      PMCID: PMC4180938          DOI: 10.1371/journal.pone.0108351

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

microRNAs (miRNAs) regulate gene expression post-transcriptionally by binding primarily to the 3′untranslated region (3′UTR) of their target mRNAs, resulting in mRNA destabilization or translational repression[1]. Genes encoding 2042 mature human miRNAs have so far been identified (miRBase v.19) [2] and miRNAs are predicted to regulate the expression of up to 60% of human protein-encoding genes [3]. The best way to understand the biological function of a miRNA is to identify the genes that it regulates. Several bioinformatics methods have been developed for miRNA target prediction, including TargetScan (www.targetscan.org), miRanda (www.microrna.org), TarBase (diana.cslab.ece.ntua.gr), PicTar (pictar.mdcberlin. de) et al. However since the mechanism of miRNA target recognition is still not fully understood, target gene prediction is not accurate and sometimes over predict [4]. In addition, a single miRNA can target hundreds of proteins and a single protein can be influenced by multiple miRNAs [5]. Thus comprehensive understanding of the phenotypic effects of miRNAs at the cellular level is currently difficult. The use of quantitative proteomic strategies to characterize targets of miRNAs has opened new avenues to miRNA biology study [6]. The method of cleavable isotope-coded affinity tags (cICAT) coupling with nano LC-MS/MS is a quantitative proteomic approach that enables rapid, comprehensive and reliable analysis of the proteomes of two comparable samples [7]. More importantly, compared with other quantitative proteomic strategies, cICAT based approach could greatly reduce the sample complexity, therefore those low abundance proteins could be readily identified. We have previously reported that miR-27a,b suppresses fat accumulation and promotes cell proliferation during hepatic stellate cells (HSCs) activation [8]. Thereafter, miR-27 has been evidenced to act as negative regulator of adipocyte differentiation [9] or lipid metabolism [10], and positive regulator of cell proliferation [11] by several groups. It has also been regarded as an oncogene in some malignant tumor [12], [13]. To further explore the possible functions and underlying mechanism of miR-27a during HSCs activation, human stellate cell line LX2/miR-27a stable transfectants was established and validated. Global protein expression profiles were compared between LX2/miR-27a and LX2/miR-neg control by cICAT-based proteomic approach. We found that out of 1267 identified proteins, 149 proteins were differentially expressed, and 75 were repressed by miR-27a overexpression among which, 15 proteins were predicted miR-27a targets. The bio-significance of miR-27a was analyzed based on the functional annotation of miR-27a regulated proteins. Individual siRNA mediated knock-down of one miR-27a regulated protein was performed to demonstrate the phenotypic effects.

Materials and Methods

1. Plasmid constructions

To construct miRNA expression plasmid, miR-27a expression fragments designed according to manufactures’ instructions, miR-27a, sense 5′-TGCTGTTCACAGTGGCTAAGTTCCGCGTTTTGGCCACTGACTGACGCGGAACTGCCACTGTGAA-3′, anti-sense 5′-CCTGTTCACAGTGGCAGTTCCGCGTCAGTCAGTGGCCAAAACGCGGAACTTAGCCACTGTGAAC-3′; were cloned into pcDNA6.2-GW/EmGFP-mir vector (Invitrogen, Carlsbad, CA) after annealing the oligonucleotides, termed as pcDNA6.2-GW/EmGFP-mir-27a. The pcDNA6.2-GW/EmGFP-mir-neg vector was provided by Invitrogen. DNA sequencing analyses confirmed the nucleotide sequences of the constructed plasmids.

2. Establishment of stable transfectants

Human hepatic stellate cell line LX2 cells [14] were maintained in DMEM (Invitrogen), supplemented with 10% FBS (Invitrogen), and were incubated in a humidified atmosphere of 5% CO2 and 95% air at 37°C. The medium was changed every 48 hours. Stable transfectants were constructed using LX2 cells that had been plated at approximately 1×105 per 60-mm diameter culture dish and cultured overnight. The cells were transfected with 5 µg pcDNA6.2-GW/EmGFP-mir-27a or mir-neg control plasmids by Lipofectamine 2000 (Invitrogen). Transfection efficiencies were checked by EmGFP expression under fluorescent microscope. Clones were selected and maintained in DMEM supplemented with 10 µg/ml Blasticidin (Invitrogen). Two stably transfected cell lines, LX2/miR-27a and LX2/miR- neg were isolated after 28 days’ selection.

3. Real-time reverse transcription PCR (RT-PCR)

Total RNA from LX2 cells was extracted using Trizol reagent (Invitrogen). cDNAs and the first-strand cDNAs of miRNA were produced according to the manufacturer’s instructions for Thermoscript RT-PCR system (Invitrogen) or NCode miRNA First-Strand cDNA Synthesis kits (Invitrogen). For the quantitative detection of miR-27a and mRNAs of interested genes, the templates and primer sets (Table S1) were mixed with SYBR qPCR master mix (TaKaRa, Dalian, China), and real-time PCR was performed using Rotor-Gene 3000 (Corbett Research, Sydney). The cycling parameters were: initial denaturing at 94°C for 15 sec, followed by 40 cycles of 94°C denaturing for 10 sec, primer annealing and extension at 60°C for 40 sec. To ensure the specificity of the amplification reaction, melting curve analysis was performed. The expression of miR-27a was normalized to U6snRNA, and mRNAs were normalized to GAPDH. Relative gene expression was presented by comparative CT method.

4. Quantitative proteomic analysis

Global protein expression profile changes of LX2/miR-27a transfectants were analyzed by a cleavable isotope-coded affinity tags (cICAT) labeling coupled with online 2D nanoLC-MS/MS based quantitative proteomic approach. cICAT reagents were from Applied Biosystems (Foster City, CA).

(A) cICAT labeling

Proteins from LX2/miR-27a and LX2/miR-neg control were labeled with isotopically heavy (H) and light (L) cICAT reagents respectively following the manufacture’s protocol. Briefly 100 µg total protein collected from LX2/miR-27a and negative control LX2/miR-neg were labeled, respectively, with isotopically light (12C for LX2/miR-neg) and heavy (13C for LX2/miR-27a ) cICAT reagents at 37°C for 2 hours. The labeled preparations were combined and digested with trypsin (Promega, madison, WI) overnight at 37°C using an enzyme-to-protein ratio of 1∶50 w/w. The resulting peptides were subsequently purified by cation exchange chromatography and avidin affinity chromatography (Applied Biosystems). The biotin group on the tag was removed by acid cleavage and the peptides were dried by vacuum-evaporation using a Speedvac™ system (Thermo Scientific).

(B) 2D nanoLC-MS/MS analysis

The dried peptides were resuspended in 80 ul of an aqueous solution containing 0.1% FA and 5% acetonitrile, the resulting solution was loaded onto a 30*0.5 mm strong cation exchange column (Agilent Technologies) and separated into 17 fractions with a step gradient of 0 mM, 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, 100 mM, 125 mM 150 mM, 200 mM, 300 mM, 400 mM, 500 mM and 900 mM, 0.1% FA, 5% acetonitrile. The elutions from SCX column were further separated on a 150*0.075 mm Vydac C18 reverse phase column (Grace, inc) in line after a nanotrap column (Agilent Technologies) using a nanoHPLC 1100 system (Agilent Technologies). Separation of the peptides was performed at 400 nl/min and was coupled to online analysis by tandem mass spectrometry using a QstarXL MS/MS system (Applied Biosystems) equipped with a nanospray ion source (Applied Biosystems). Elution of the peptides into the mass spectrometer was performed with a linear gradient from 95% mobile phase A (0.1% FA, 99.9% water) to 35% mobile phase B (0.1% FA, 99.9% acetonitrile) over 120 minutes followed by 80% mobile phase B for 10 min. The peptides were detected in positive ion mode using an IDA (information dependent acquisition) method in which three most abundant ions detected in a MS scan were selected for MS/MS analysis. Two independent analyses were performed.

(C) Data Analysis

For protein identification and quantification, all MS/MS spectra were searched against the IPI human protein database (V3.83) using ProteinpilotTM 3.0.1 (Applied Biosystem). The software compares relative intensity of proteins present in samples based on the intensity of reporter ions released from each labeled peptide and automatically calculates protein ratios and p-values for each protein. For protein identification, 95% confidence was used and the corresponding FDR <1%.

5. Bio-functional analysis of differentially expressed proteins

GOfact (http://61.50.138.118/gofact/cgi/gofact2009.cgi) strategy [15], [16] which based on the structured and controlled vocabularies - Gene Ontology (GO), and the GO annotation from related databases was used to identify the functional distribution and the enriched functional categories of miR-27a regulated proteins in LX2 cells. The subcellular locations and bio-functions of proteins were also annotated by Protein Knowledgebase (UniprotKB) (http://www.uniprot.org/).

6. Transfection of siRNA

Transfection of siRNA was performed according to the manufacturer’s protocol (Sigma, Saint Louis, MO). LX2 and LX2/miR-27a transfectants cultured in 24-well plates or 6-cm dishes were transfected at 50–70% confluence with siRNA targeting human four and a half LIM domains 1 (FHL1) by means of the siRNA transfection reagent RNAiMAX (Invitrogen). NTC (Non-targeting control) siRNA was transfected simultaneously as negative control. After 48 h transfection, the efficiency of siRNA-mediated mRNA degradation was assessed by real-time RT–PCR.

7. Proliferation and migration assays

The effects of siRNA transfection on LX2/miR-27a transfectants migration were measured by using a modified Boyden chamber assay. Two days after transfection, 2×104 cells in serum-free DMEM were plated on the upper chamber of each Transwell (Costar, Corning Inc., NY) with 8 µm pores, while the lower chamber contained 800 µl completed medium. Transfected cells were incubated for 16 h at 37°C in 5% CO2. Non-migrating cells were carefully removed from the upper surface of the membrane with cotton swabs. Membranes were stained with crystal violet and mounted onto glass slides. Migration was quantified by counting cells in eight 200x microscopic fields. Forty-eight hours after siRNAs transfection, the cell proliferation of LX2 cells was detected by incorporation of 5-ethynyl-2′-deoxyuridine (EdU) with the Cell-Light EdU Apollo 567 Cell Proliferation Kit (Ruibo Biotech, Guangzhou, China). According to the kit’s protocol, cells were incubated with 10 µM EdU for 16 h before fixation, permeabilization, and EdU staining. EdU was detected by Apollo fluorescent dye at 567 nm wave length and nuclei were counterstained with 5 µg/ml Hoechst 33342. For each well, eight fields were counted at a 200x magnification. The results were expressed as the labeling index according to the following formula: number of EdU-positive nuclei×100/number of total nuclei.

8. Statistics assay

Data are expressed as the mean ± SD. Comparison between groups were made by Student’s t test (two tailed) or one-way ANOVA followed by Tukey's multiple comparison test. The relationship between two data sets was analyzed by linear regression. Differences were considered significant if P<0.05. Unless otherwise specified, all assays were performed in triplicate.

Results and Discussion

1. Biological characterization of LX2/miR-27a stable transfectants

To explore the biological effects of miR-27a overexpression on HSCs, we established a LX2/miR-27a stable transfectants (Figure 1A). The expression of mature miR-27a increased significantly in LX2/miR-27a stable transfectants (Figure 1B). As it was expected, LX2/miR-27a stable transfectants showed increased cell proliferation and migration compared to LX2/miR- neg stable transfectants (Figure 1C and D). The influence of miR-27a over expression on lipid metabolism was not measurable due to the already activated HSC phenotype of LX2 cell line.
Figure 1

Establishment and biological characters of LX2/miR-27a, LX2/miR-neg stable transfectants.

(A) Almost all cells in the positive clone expressed EmGFP (green), original magnification ×200. (B) The expression of miR-27a in LX2/miR-27a, LX2/miR-neg stable transfectants. (C) Over-expression of miR-27a promoted LX2 cell proliferation. (D) miR-27a over-expression facilitated LX2 migration. **P<0.01 compared with LX2/miR-neg.

Establishment and biological characters of LX2/miR-27a, LX2/miR-neg stable transfectants.

(A) Almost all cells in the positive clone expressed EmGFP (green), original magnification ×200. (B) The expression of miR-27a in LX2/miR-27a, LX2/miR-neg stable transfectants. (C) Over-expression of miR-27a promoted LX2 cell proliferation. (D) miR-27a over-expression facilitated LX2 migration. **P<0.01 compared with LX2/miR-neg.

2. Identification of miR-27a regulated proteins by cICAT-based proteomic analyses

Global protein expression profiles were compared between LX2/miR-27a and LX2/miR-neg stable transfectants by a cICAT-based quantitative proteomic approach (Figure 2A–C). Two biological replications were analyzed (Table S2). To estimate the analytical reproducibility of our proteomics study, linear regression analyses were performed on H/L ratios of duplicate analyses of samples 1 and 2 (Figure 2D). Pearson correlation coefficient for sample 1 and 2 was 0.8039 (P<0.01). Thus, the ratios of the two duplicate analyses were significantly positively correlated, indicating the good analytical reproducibility of the on-line 2D LC/MS/MS system. Thereby, spectral data from two duplicate analyses were merged and searched again to enhance the coverage of protein identification and to “average” the expression ratios of proteins identified in samples 1 and 2 (Table S3).
Figure 2

Protein samples from LX2/miR-27a and LX2/miR-neg were compared by cleavable isotope-coded affinity tag (cICAT)-based quantitative proteomic analysis - identification and quantitation of ATP-citrate synthase.

(A) Total ion chromatogram (TIC) indicating cICAT-labeled peptides eluting from a reverse phase column. (B) Expanded MS spectrum view of a pair of peaks showing the differential expression between peptides labeled with the isotopically light and heavy cICAT reagent. (C) MS/MS spectrum analysis of the light-cICAT labeled triply charged peptide (681.4 m/z) showed in (B) led to identification of a peptide with sequence GVTIIGPATVGGIKPGCFK (ICAT-C(C)@17), unique to the ATP-citrate synthase (ACLY), a predicted target of miR-27a. The labels b and y designated the N- and C- terminal fragments, respectively, of the peptide produced by breakage at the peptide bond in the mass spectrometer. The number represents the number of N- or C- terminal residues present in the peptide fragment. (D) Venn diagram depicting the overlap of proteins identified in two independent cICAT experiments. Numbers in parentheses indicate the number of identified proteins for each sample. To examine the biological reproducibility, linear regression analyses were performed on H/L ratios (LX2/miR-27a/LX2/miR-neg) of two independent analyses. Pearson correlation coefficient between samples 1 and 2 was 0.8039, P<0.01.

Protein samples from LX2/miR-27a and LX2/miR-neg were compared by cleavable isotope-coded affinity tag (cICAT)-based quantitative proteomic analysis - identification and quantitation of ATP-citrate synthase.

(A) Total ion chromatogram (TIC) indicating cICAT-labeled peptides eluting from a reverse phase column. (B) Expanded MS spectrum view of a pair of peaks showing the differential expression between peptides labeled with the isotopically light and heavy cICAT reagent. (C) MS/MS spectrum analysis of the light-cICAT labeled triply charged peptide (681.4 m/z) showed in (B) led to identification of a peptide with sequence GVTIIGPATVGGIKPGCFK (ICAT-C(C)@17), unique to the ATP-citrate synthase (ACLY), a predicted target of miR-27a. The labels b and y designated the N- and C- terminal fragments, respectively, of the peptide produced by breakage at the peptide bond in the mass spectrometer. The number represents the number of N- or C- terminal residues present in the peptide fragment. (D) Venn diagram depicting the overlap of proteins identified in two independent cICAT experiments. Numbers in parentheses indicate the number of identified proteins for each sample. To examine the biological reproducibility, linear regression analyses were performed on H/L ratios (LX2/miR-27a/LX2/miR-neg) of two independent analyses. Pearson correlation coefficient between samples 1 and 2 was 0.8039, P<0.01. In the present study, 1267 non-redundant proteins were identified with unique accession numbers (score ≥1.3, i.e. confidence ≥95%), among which 1171 were quantified (Table S3). In the present study, based on the expression ratio of housekeeping proteins such as β-actin (ACTB, H/L = 1.0637) and tubulin β chain (TUBB, H/L = 1.0274), a differential protein expression ratio of 1.5 was selected as significant threshold [17], thus 149 (12.72%) proteins were differentially expressed. Of these 149 proteins, 74 were up-regulated (i.e. H/L ≥1.5) and 75 were down-regulated (i.e. H/L ≤0.6667), the number of up-regulated proteins was almost equal to that of down-regulated (Table S4). Compared with our previous study on HSCs activation [18], the extent of protein expression changes is relatively small in miR-27a overexpressed LX2, only 6 proteins increase up to 3-fold (i.e. H/L ≥3.0) and 2 proteins reduced below 3-fold (i.e. H/L ≤0.3333). The results also corroborated a recent finding that a single miRNA could regulate the production of hundreds of proteins, but the regulation was typically relatively mild [5].

3. Correlation between miR-27a target prediction and down-regulated proteins in LX2/miR-27a identified by cICAT

Next, we tried to figure out how miR-27a target prediction correlated with miR-27a down-regulated proteins in HSCs identified by cICAT-based proteomics analyses. TargetScan is one of the widely recognized databases for biological targets prediction of miRNAs [19]. By searching TargetScan Human Release 6.2 (http://www.targetscan.org/vert_61/), we found that only 2 out of the 75 down-regulated proteins were predicted targets of miR-27a, namely SMAD5 (mothers against decapentaplegic homolog 5) and ACLY (ATP-citrate synthase). SMAD5, a key component of TGF-beta signaling pathway, is an experimentally confirmed target of miR-27 [20]. ACLY is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues and has a central role in de novo lipid synthesis. We further searched the predicted consequential pairing of miR-27a target region in the 3′ UTR of the remaining 73 down-regulated proteins in TargetScan Human Release 6.2. As shown in Table 1, 15 (20%) out of 75 down-regulated proteins could be potential targets of miR-27a, while the other 60 (80%) down-regulated proteins did not have consequential pairing of miR-27a target region in the 3′ UTR. Moreover, 74 proteins were even up-regulated in LX2/miR-27a stable transfectants. These findings suggested that the miRNA responsive proteins were not necessarily the predicted endogenous targets, they also reflected indirect effects. The underlying mechanisms deserve further investigation, as it has also been reported that miRNAs can even stimulate gene expression post transcriptionally by direct and indirect mechanisms [21].
Table 1

Predicted miR-27a Targets among Down-regulated Proteins in LX2/miR-27a Identified by cICAT.

Gene symbolAccessionPredicted consequentialpairing of target region(top) and miRNA (bottom)Seed matchContext scoreContext scorepercentilePCT * H/L
ACLY NM_001096Position 697–703 of ACLY 3' UTR5′ …UGGAAAUGCAGAAAGCUGUGAAA…7mer-1A−0.13730.670.6597
||||||
hsa-miR-27a 3′ CGCCUUGAAUCGGUGACACUU
AP3D1 NM_001077523Position 187–193 of AP3D1 3 UTR5′ …UGACCAUCCUUUUUUACUGUGAC…7mer-m8−0.2087<0.10.5462
||| |||||||
hsa-miR-27a 3′ CGCCUUGAAUCGGUGACACUU
ATP2A2 NM_170665Position 2249–2256 of ATP2A2 3 UTR5′ …AAAAAAAUCAGCCUUACUGUGAA…8mer>−0.032<0.10.6095
|||||||
hsa-miR-27a 3′ CGCCUUGAAUCGGUGACACUU
COPA NM_001098398Position 1233–1239 of COPA 3 UTR5′ …UGAGGACCUAAACUGCUGUGAAA…7mer-1A−0.1163<0.10.6641
||||||
hsa-miR-27a 3′ CGCCUUGAAUCGGUGACACUU
DYNLL2 NM_080677Position 535–541 of DYNLL2 3 UTR5′ …AGAAUAUUCCACUGAACUGUGAU…7mer-m8−0.12710.340.4487
|||||||
hsa-miR-27a 3′ CGCCUUGAAUCGGUGACACUU
FN1 NM_002026Position 431–437 of FN1 3 UTR5′ …AAGCAUGAUCUUGUU-ACUGUGAU…7mer-m8−0.2289<0.10.5669
||| |||||||
hsa-miR-27a 3′ CGCCUUGAAUCGGUGACACUU
Position 742–748 of FN1 3 UTR5′ …CGGGGGAAAUAAUUCCUGUGAAU…7mer-1A−0.1371<0.1
||||||
hsa-miR-27a 3′ CGCCUUGAAUCGGUGACACUU
GNPNAT1 NM_198066Position 175–181 of GNPNAT1 3 UTR5′ …GGCUGGUGGGACAUGCUGUGAAU…7mer-1A−0.1268<0.10.5175
||||||
hsa-miR-27a 3′ CGCCUUGAAUCGGUGACACUU
Position 668–674 of GNPNAT1 3 UTR5′ …UACCACUUGUCUUUUCUGUGAAU…7mer-1A−0.1060<0.1
|||| ||||||
hsa-miR-27a 3′ CGCCUUGAAUCGGU–GACACUU
H6PD NM_004285Position 1513–1519 of H6PD 3 UTR5′ …GAGCAUAGGUUGGGGACUGUGAU…7mer-m8> −0.020<0.10.5198
|||||||
hsa-miR-27a 3′ CGCCUUGAAUCGGUGACACUU
Position 5755–5761 of H6PD 3 UTR5′ …UGUGCCGGAGUGGGAACUGUGAU…7mer-m8−0.0227<0.1
|||||||
hsa-miR-27a 3′ CGCCUUGAAUCGGUGACACUU
HSD17B12 NM_016142Position 1071–1078 of HSD17B12 3 UTR5′ …AAGAAAGAAUUCAAUACUGUGAA…8mer−0.3397<0.10.3966
|||||||
hsa-miR-27a 3′ CGCCUUGAAUCGGUGACACUU
PAK2 NM_002577Position 2076–2082 of PAK2 3 UTR5′ …CAACGAGAUGAGAAGACUGUGAU…7mer-m8> −0.022<0.10.5688
|||||||
hsa-miR-27a 3′ CGCCUUGAAUCGGUGACACUU
PPM1B NM_001033557Position 177–184 of PPM1B 3 UTR5′ …AUUAAACUUUAAAUGACUGUGAA…8mer−0.4099<0.10.4537
||||| |||||||
hsa-miR-27a 3′ CGCCUUGAAUCGG–UGACACUU
RAB23 NM_016277Position 982–988 of RAB23 3 UTR5′ …GUCAUUCAGGAGGUCCUGUGAAG…7mer-1A−0.0123<0.10.6407
||||||
hsa-miR-27a 3′ CGCCUUGAAUCGGUGACACUU
SEC61A1 NM_013336Position 197–204 of SEC61A1 3 UTR5′ …GCACUGGCAAAAAGAACUGUGAA…8mer−0.3095<0.10.5849
|||||||
hsa-miR-27a 3′ CGCCUUGAAUCGGUGACACUU
SMAD5 NM_001001419Position 72–78 of SMAD5 3 UTR5′ …ACUUUGAGUACAGAUACUGUGAG…7mer-m8−0.20870.750.6113
|||||||
hsa-miR-27a 3′ CGCCUUGAAUCGGUGACACUU
Position 2427–2433 of SMAD5 3 UTR5′ …UUAUUGGUGUUUUCUACUGUGAG…7mer-m8−0.0331<0.1
|||||||
hsa-miR-27a 3′ CGCCUUGAAUCGGUGACACUU
SPTBN1 NM_178313Position 2130–2136 of SPTBN1 3 UTR5′ …UCAUUUGAUCAUAGCACUGUGAU…7mer-m8−0.1681<0.10.6351
|||||||
hsa-miR-27a 3′ CGCCUUGAAUCGGUGACACUU

* PCT, the probability of conserved targeting.

* PCT, the probability of conserved targeting.

4. Validation of proteomic findings by real-time RT-PCR

Six of the differentially expressed proteins identified in two replicate cICAT assays, ATP-citrate synthase (ACLY), leukotriene A4 hydrolase (LTA4H), cathepsin L1 (CTSL1), thrombospondin-1 precursor (THBS1), four and a half LIM domains 1 (FHL1) and high-mobility group box 1(HMGB1), were validated by real-time RT-PCR. The relationship between fold changes of protein detected by cICAT and fold changes of protein encoding gene detected by PCR was assessed by linear regression analysis. Pearson correlation coefficient for cICAT and real-time RT-PCR expression data was 0.9745 (P = 0.001). The PCR results confirmed the expression pattern observed in cICAT quantitative proteomics analysis (Figure 3).
Figure 3

Validation of cICAT proteomic findings by real-time RT-PCR.

(A) The expression of 6 genes encoding selected proteins in LX2/miR-27a stable transfectants. (B) Linear regression analysis of the fold change of protein and encoding gene in LX2/miR-27a detected by cICAT and RT-PCR respectively. ACLY, ATP-citrate synthase; LTA4H, leukotriene A4 hydrolase; CTSL1, cathepsin L1; THBS1, thrombospondin-1 precursor; FHL1, four and a half LIM domains 1; HMGB1, high-mobility group box 1. *P<0.05, **P<0.01 compared with LX2/miR-neg.

Validation of cICAT proteomic findings by real-time RT-PCR.

(A) The expression of 6 genes encoding selected proteins in LX2/miR-27a stable transfectants. (B) Linear regression analysis of the fold change of protein and encoding gene in LX2/miR-27a detected by cICAT and RT-PCR respectively. ACLY, ATP-citrate synthase; LTA4H, leukotriene A4 hydrolase; CTSL1, cathepsin L1; THBS1, thrombospondin-1 precursor; FHL1, four and a half LIM domains 1; HMGB1, high-mobility group box 1. *P<0.05, **P<0.01 compared with LX2/miR-neg.

5. Overall distribution of miR-27a regulated proteins in LX2 cells

The subcellular location and bio-function of miR-27a regulated proteins in LX2 cells were categorized by using Protein Knowledgebase (UniprotKB) (Table S4). The subcellular localization of miR-27a regulated proteins is wide, including cytoplasm, nucleus, plasma membrane and extracellular space (Figure 4A). Enzymes, kinase, peptidase and phosphatase constituted the largest part of miR-27a regulated proteins in LX2 cells (49 out of 134 annotated differentially expressed proteins, 37%), followed by transcription regulator (11 out of 134, 8%). Therefore, by preferentially influencing the expression of enzymes and transcription regulators, miR-27a could perform its bio-function with high efficiency (Figure 4B).
Figure 4

Overall distribution of miR-27a regulated proteins in LX2 cells.

(A) Cell location and (B) Functional distribution of all the 134 differentially expressed proteins.

Overall distribution of miR-27a regulated proteins in LX2 cells.

(A) Cell location and (B) Functional distribution of all the 134 differentially expressed proteins.

6. Bio-functional analysis of differentially expressed proteins in LX2/miR-27a stable transfectants

GOfact was used to identify the enriched functional categories. The data of functional categorizing was inspiring, according to their molecular functions, most of the altered proteins could be well assigned into the categories involved in de novo lipid synthesis, cell proliferation, apoptosis, cell adhesion and migration, which were closely associated with the mechanisms participating in HSCs activation (Table 2, 3).
Table 2

Functional Categories of Down-regulated Proteins in LX2/miR-27a Compared with LX2/miR-neg (H/L ≤0.6667).

Functional CategoriesAccessionGene SymbolNameH/LFunctionalCategoriesAccessionGene SymbolNameH/L
Lipid metabolismCell adhesionand mobility
IPI00021290.5ACLYATP-citrate synthase0.6597IPI00394837.2RAC1ras-related C3 botulinum toxin substrate 1 isoform Rac1c0.6298
IPI00219077.4LTA4HIsoform 1 of Leukotriene A-4 hydrolase0.3066IPI00031008.1TNCIsoform 1 of Tenascin precursor0.6217
IPI00007676.3HSD17B12Estradiol 17-beta-dehydrogenase 120.3966IPI00845263.1FN1fibronectin 1 isoform 2 preproprotein0.5669
IPI00022793.5HADHBTrifunctional enzyme subunit beta, mitochondrial precursor0.4545IPI00218803.2FBLN1Isoform B of Fibulin-1 precursor0.4012
IPI00169285.5P76Putative phospholipase B-like 2 precursor0.6120IPI00296099.6THBS1Thrombospondin-1 precursor0.2069
Glycolysis and TCA IPI00011285.1CAPN1Calpain-1 catalytic subunit0.5367
IPI00217143.3SDHA57 kDa protein0.6594IPI00844394.1CYR6142 kDa protein0.5468
IPI00790739.1ACO2Aconitase 2, mitochondrial0.4723IPI00872386.1BCAR1Breast cancer anti-estrogen resistance protein 10.5436
IPI00291006.1MDH2Malate dehydrogenase, mitochondrial precursor0.5272IPI00009198.3TFPI2Tissue factor pathway inhibitor 2 precursor0.4616
IPI00607861.2H6PDGDH/6PGL endoplasmic bifunctional protein precursor0.5198IPI00007117.1SERPINB2Plasminogen activator inhibitor 2 precursor0.5357
IPI00643196.1PFKPPhosphofructokinase, platelet0.5484 Cytoskeleton
IPI00418262.4ALDOCFructose-bisphosphate aldolase C0.5835IPI00871932.1SPTBN1276 kDa protein0.6351
Cell growth related IPI00456969.1DYNC1H1Cytoplasmic dynein 1 heavy chain 10.6607
IPI00869040.1NUBP1Isoform 2 of Nucleotide-binding protein 10.6392IPI00062037.1DYNLL2Dynein light chain 2, cytoplasmic0.4487
IPI00419273.5CUL4AIsoform 1 of Cullin-4A0.5050IPI00146935.4DNM1LIsoform 1 of Dynamin-1-like protein0.4586
IPI00788802.1TKTTransketolase variant (Fragment)0.6588 Ubl conjugation pathway
Transcription/translation regulator IPI00871372.1HECTD1HECT domain containing 10.3967
IPI00025091.3RPS1140S ribosomal protein S110.6222IPI00645078.1UBA1Ubiquitin-like modifier-activating enzyme 10.5802
IPI00219156.7RPL3060S ribosomal protein L300.6370 Miscellaneous
IPI00738381.2EEF1GElongation factor 1-gamma0.6504IPI00384428.3BPHLIsoform 1 of Valacyclovir hydrolase precursor0.4093
IPI00017730.1SMAD5Mothers against decapentaplegic homolog 50.6113IPI00746782.1MPST3-mercaptopyruvate sulfurtransferase variant (Fragment)0.4171
IPI00215888.4SRP72Signal recognition particle 72 kDa protein0.6129IPI00026612.1PPM1BIsoform Beta-1 of Protein phosphatase 1B0.4537
IPI00376317.4EDC4Isoform 1 of Enhancer of mRNA-decapping protein 40.5609IPI00019568.1F2Prothrombin precursor (Fragment)0.5520
Transport IPI00019903.1CCDC44Coiled-coil domain-containing protein 440.5392
IPI00008034.1RAB23Ras-related protein Rab-230.6407IPI00554521.2FTH1Ferritin heavy chain0.6172
IPI00791106.2SCAMP4Isoform 3 of Secretory carrier-associated membrane protein 40.6565IPI00291136.4COL6A1Collagen alpha-1(VI) chain precursor0.5397
IPI00060287.3C3orf31MMP37-like protein, mitochondrial precursor0.6380IPI00872430.1RPS825 kDa protein0.5161
IPI00029557.3GRPEL1GrpE protein homolog 1, mitochondrial precursor0.6625IPI00827508.2RPL10A25 kDa protein0.5912
IPI00646493.1COPAcoatomer protein complex, subunit alpha isoform 10.6641IPI00061525.3GNPNAT1Glucosamine 6-phosphate N-acetyltransferase0.5175
IPI00219078.5ATP2A2Isoform SERCA2B of Sarcoplasmic/endoplasmic reticulum calcium ATPase 20.6095IPI00873294.1BLMH61 kDa protein0.6072
IPI00026530.4LMAN1Protein ERGIC-53 precursor0.4662IPI00289159.3GLSIsoform KGA of Glutaminase kidney isoform, mitochondrial precursor0.6137
IPI00178314.1STXBP6Isoform 1 of Syntaxin-binding protein 60.5278IPI00219029.3GOT1Aspartate aminotransferase, cytoplasmic0.6165
IPI00411453.3AP3D1Isoform 1 of AP-3 complex subunit delta-10.5462IPI00012887.1CTSL1Cathepsin L1 precursor0.6208
IPI00218466.6SEC61A1Isoform 1 of Protein transport protein Sec61 subunit alpha isoform 10.5849IPI00022334.1OATOrnithine aminotransferase, mitochondrial precursor0.6457
IPI00022881.1CLTCL1Isoform 1 of Clathrin heavy chain 20.5929IPI00295386.7CBR1Carbonyl reductase [NADPH] 10.6148
IPI00550382.2SLC29A1Equilibrative nucleoside transporter 10.5941IPI00413986.2Ribosomal protein L10.5311
IPI00328181.1TCIRG1T-cell, immune regulator 1 isoform a0.5663 Hypothetical proteins
Apoptosis IPI00738655.2LOC653781similar to protein expressed in prostate, ovary, testis, and placenta 20.6075
IPI00010277.1TNFRSF12AIsoform 1 of Tumor necrosis factor receptor superfamily member 12A precursor0.6016IPI00788011.2LOC728622similar to S-phase kinase-associated protein 1A0.5591
IPI00419979.3PAK2Serine/threonine-protein kinase PAK 20.5688IPI00888100.1LOC390956similar to peptidylprolyl isomerase A-like0.5376
IPI00847689.1HTATIP2HIV-1 Tat interactive protein 2, 30kDa isoform a0.6114IPI00847300.1Similar to Voltage-dependent anion-selective channel protein 10.5335
IPI00888597.1LOC100129762similar to KIAA03670.5103
IPI00737530.1LOC653888similar to p41-Arc0.4929

Proteins from LX2/miR-27a were labeled with heavy isotope (H) tagging and those from LX2/miR-neg were labeled with light isotope (L) tagging. Data were from two independent cICAT-based quantitative analyses.

Table 3

Functional Categories of Up-regulated Proteins in LX2/miR-27a Compared with LX2/miR-neg (H/L ≥1.5).

Functional CategoriesAccessionGene SymbolNameH/LFunctional CategoriesAccessionGene SymbolNameH/L
Lipid metabolismApoptosis
IPI00872459.2PRKAA1Uncharacterized protein PRKAA11.9474IPI00893062.1XRCC6X-ray repair complementing defective repair in Chinese hamster cells 61.5110
DNA replication and cell growth IPI00010882.3DFFAIsoform DFF45 of DNA fragmentation factor subunit alpha (Fragment)2.0058
IPI00163608.1PARD3Isoform 5 of Partitioning-defective 3 homolog1.5964IPI00006904.1AVENCell death regulator Aven1.5283
IPI00219420.3SMC3Structural maintenance of chromosomes protein 31.5081 Cell adhesion and mobility
IPI00791117.1TK129 kDa protein1.7692IPI00010676.1PLAURIsoform 1 of Urokinase plasminogen activator surface receptor precursor1.5458
IPI00465044.2RCC2Protein RCC21.7793 Cytoskeleton
IPI00419258.4HMGB1High mobility group protein B11.6722IPI00220278.5MYL9Myosin regulatory light chain 2, smooth muscle isoform1.5910
IPI00031517.1MCM6DNA replication licensing factor MCM61.6907IPI00328113.2FBN1Fibrillin-1 precursor1.5611
IPI00013679.1DUTIsoform DUT-M of Deoxyuridine 5-triphosphate nucleotidohydrolase, mitochondrial precursor1.6977IPI00013991.1TPM2Isoform 1 of Tropomyosin beta chain1.6519
IPI00384967.3ALDH1A3Putative uncharacterized protein DKFZp686G1675 (Fragment)1.8431IPI00442894.3TPM1Tropomyosin alpha-1 chain1.8151
IPI00002135.1TACC3Transforming acidic coiled-coil-containing protein 31.6166IPI00336047.5MYO9BIsoform Long of Myosin-IXb2.3887
IPI00014572.1SPARCSPARC precursor1.7071IPI00398735.3CNN2calponin 2 isoform b1.6890
IPI00034181.1RBBP9Isoform 1 of Retinoblastoma-binding protein 91.7084IPI00844425.1C3orf10Isoform 2 of Probable protein BRICK12.0215
IPI00014398.2FHL1Four and a half LIM domains 1 variant2.5284IPI00183002.6PPP1R12AIsoform 1 of Protein phosphatase 1 regulatory subunit 12A1.9959
Transcription/translation regulator IPI00478231.2RHOATransforming protein RhoA precursor1.5511
IPI00011675.1SP100Isoform Sp100-HMG of Nuclear autoantigen Sp-1001.5817 Ubl conjugation pathway
IPI00604620.3NCLNCL Isoform 1 of Nucleolin1.6097IPI00874175.1UBE2G2Ubiquitin carrier protein (Fragment)1.8507
IPI00647163.1TCEAL4Isoform 2 of Transcription elongation factor A protein-like 41.5207 Miscellaneous
IPI00219097.4HMGB2High mobility group protein B21.7124IPI00163230.5COPS6COP9 signalosome complex subunit 66.9577
IPI00853059.2FUBP1Isoform 2 of Far upstream element-binding protein 11.7293IPI00477962.3UAP1L1Isoform 1 of UDP-N-acetylhexosamine pyrophosphorylase-like protein 12.0940
IPI00167985.5ZNF579Zinc finger protein 5791.8441IPI00296141.3DPP7Dipeptidyl-peptidase 2 precursor1.8415
IPI00007941.4HEXIM1Protein HEXIM11.8459IPI00026087.1BANF1Barrier-to-autointegration factor1.6141
IPI00028122.1PSIP1Isoform 1 of PC4 and SFRS1-interacting protein1.9394IPI00807702.1TNIP1NEF-associated factor 11.5713
IPI00855957.2KHSRPIsoform 2 of Far upstream element-binding protein 22.0065IPI00101968.3DBNLIsoform 3 of Drebrin-like protein1.6175
IPI00215801.1RBM39Isoform 2 of RNA-binding protein 392.0987IPI00093057.6CPOXCoproporphyrinogen III oxidase, mitochondrial precursor1.5958
IPI00871695.1DEK48 kDa protein4.8877IPI00103925.2IRGQImmunity-related GTPase family Q protein1.5803
IPI00024662.1CBX5Chromobox protein homolog 51.8359IPI00894202.1C2orf30chromosome 2 open reading frame 30 isoform 21.5903
IPI00297579.4CBX3Chromobox protein homolog 31.7487IPI00550308.1RBM12RNA-binding protein 121.5255
IPI00021417.3SART1U4/U6.U5 tri-snRNP-associated protein 11.5333IPI00031622.3CHCHD6Coiled-coil-helix-coiled-coil-helix domain-containing protein 63.5705
IPI00555857.1SFRS5CS0DF038YO05 variant (Fragment)1.7597IPI00178750.3NIP30NEFA-interacting nuclear protein NIP302.2462
IPI00026957.1WBP4WW domain-binding protein 41.7331IPI00304922.1LSMD1Isoform 1 of LSM domain-containing protein 112.1912
IPI00215884.4SFRS1Isoform ASF-1 of Splicing factor, arginine/serine-rich 11.5994IPI00396321.1LRRC59Leucine-rich repeat-containing protein 591.7094
IPI00290461.3EIF3JEukaryotic translation initiation factor 3 subunit J1.5853IPI00297263.6HEG1Isoform 1 of Protein HEG homolog 1 precursor1.9231
IPI00552639.2EIF4G1Isoform 1 of Eukaryotic translation initiation factor 4 gamma 11.6356IPI00419836.1DCBLD2Isoform 1 of Discoidin, CUB and LCCL domain-containing protein 2 precursor1.8740
Transport Hypothetical proteins
IPI00848342.1LTFLactotransferrin precursor1.6590IPI00006932.3LUC7L2Isoform 1 of Putative RNA-binding protein Luc7-like 21.5778
IPI00303402.7RNUXARNA U small nuclear RNA export adapter protein1.5796IPI00333014.3C13orf3Isoform 1 of Uncharacterized protein C13orf31.6993
IPI00449201.2ATG3Isoform 2 of Autophagy-related protein 31.5491IPI00013832.3GATCGatC-like protein1.5144
IPI00871988.1SFXN3Uncharacterized protein SFXN31.6101IPI00795769.152 kDa protein2.0541
IPI00641384.2SEC16ASEC16 homolog A3.0693IPI00472879.3Novel protein similar to Pre-B cell enhancing factor1.5245
IPI00872163.1ATP2A1Similar to ATPase, Ca++ transporting, cardiac muscle, fast twitch 13.2500

Proteins from LX2/miR-27a were labeled with heavy isotope (H) tagging and those from LX2/miR-neg were labeled with light isotope (L) tagging. Data were from two independent cICAT-based quantitative analyses.

Proteins from LX2/miR-27a were labeled with heavy isotope (H) tagging and those from LX2/miR-neg were labeled with light isotope (L) tagging. Data were from two independent cICAT-based quantitative analyses. Proteins from LX2/miR-27a were labeled with heavy isotope (H) tagging and those from LX2/miR-neg were labeled with light isotope (L) tagging. Data were from two independent cICAT-based quantitative analyses. A large number of the down-regulated proteins were involved in de novo lipid synthesis (Figure 5), among which three groups were most concerned: (1) aconitase (ACO2), malate dehydrogenase (MDH2), and ATP-citrate synthase (ACLY), which are important enzymes participating in tricarboxylic acid cycle and favor the production of acetyl-CoA; (2) glucose 1-dehydrogenase/6-phosphogluconolactonase (H6PD), the rate-limiting enzyme for pentose phosphate pathway that supplies NADPH; (3) 6-phosphofructokinase type C (PFKP) and fructose-bisphosphate aldolase C (ALDOC), are involved in glycolytic pathway that provides glycerol-3-phosphate, and the former is a rate-limiting enzyme (Table 2). Acetyl-CoA, NADPH and glycerol-3-phosphate are all required in de novo lipid synthesis. On the other hand, one negative regulator of lipid synthesis called 5′-AMP-activated protein kinase catalytic subunit alpha-1 (PRKAA1) was significantly up-regulated(Table 3). By phosphorylation, PRKAA1 can inactivate acetyl-CoA carboxylase that catalyzes the rate-limiting reaction in the biosynthesis of long-chain fatty acids [22], [23]. So miR-27a may affect HSCs fat accumulation by directly regulating a group of genes that are involved in the biosynthesis of triglyceride.
Figure 5

Altered proteins that are involved in metabolism processes related to de novo lipid synthesis: aconitase 2 (ACO2) and malate dehydrogenase (MDH2), which participate in tricarboxylic acid cycle (TAC) (i) decreased; ATP-citrate synthase (ACLY), the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA (ii) decreased; 5′-AMP-activated protein kinase catalytic subunit alpha-1 (PRKAA1) that repress the synthesis of malonyl-CoA (iii) by phosphorylation of acetyl-CoA carboxylase increased; glucose 1-dehydrogenase/6-phosphogluconolactonase (H6PD), the rate-limiting enzyme in pentose phosphate pathway (PPP) (iv) decreased; 6-phosphofructokinase type C (PFKP) that acts as the rate-limiting enzyme, fructose-bisphosphate aldolase C (ALDOC), which are involved in glycolytic pathway(v) decreased.

Altered proteins that are involved in metabolism processes related to de novo lipid synthesis: aconitase 2 (ACO2) and malate dehydrogenase (MDH2), which participate in tricarboxylic acid cycle (TAC) (i) decreased; ATP-citrate synthase (ACLY), the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA (ii) decreased; 5′-AMP-activated protein kinase catalytic subunit alpha-1 (PRKAA1) that repress the synthesis of malonyl-CoA (iii) by phosphorylation of acetyl-CoA carboxylase increased; glucose 1-dehydrogenase/6-phosphogluconolactonase (H6PD), the rate-limiting enzyme in pentose phosphate pathway (PPP) (iv) decreased; 6-phosphofructokinase type C (PFKP) that acts as the rate-limiting enzyme, fructose-bisphosphate aldolase C (ALDOC), which are involved in glycolytic pathway(v) decreased. Proteins involved in cell adhesion and mobility constituted another major group of down-regulated proteins (10 out 75), including Tenascin (TNC) [24], fibronectin 1 (FN1) [25] and Fibulin-1 (FBLN1) [26], which correlated with reduced adhesion and increased migration of miR-27a stable transfectants (Figure 1D). Over expression of miR-27a also up-regulated a group of factors that favorite proliferation of HSCs. Twelve out of 74 up-regulated proteins were DNA replication and growth-related, and 19 proteins were important transcription/translation regulators, e.g. DNA replication licensing factor MCM6 (MCM6), transcription elongation factor A protein-like 4 (TCEAL4), eukaryotic translation initiation factor 3 subunit J (EIF3J), eukaryotic translation initiation factor 4 gamma 1 (EIF4G1), retinoblastoma-binding protein 9 (RBBP9) [27] and FHL1 [28]. The present proteomic study not only provided the possible mechanism underlying the previously reported miR-27 function in HSCs, but also casted new light on a novel role of miR-27a in myogenesis, which was consistent with the myofibroblast trans-differentiation during HSCs activation. In 9 up-regulated cytoskeleton related proteins, 4 are structural constituents of muscle, including tropomyosin alpha-1 chain (TPM1), tropomyosin beta chain (TPM2), myosin-IXb (MYO9B) and myosin regulatory light chain 2 (MYL9); 4 are in regulation of actomyosin structure and function, including protein phosphatase 1 regulatory subunit 12A (PPP1R12A) [29]; calponin 2 (CNN2) [30]; transforming protein RhoA (RHOA) [31] and FHL1 [32]. The up-regulation of TPM1, MYO9B and MYL9 by miR-27a in LX2 cells was further validated by RT-PCR (Figure S1). In a previous study, it has also been evidenced that miR-27a can up-regulate cardiac myosin heavy chain (MHC) gene (β-MHC) expression via thyroid hormone signaling [33]. And miR-27a has also been reported to be able to influence muscle stem cell behavior [34]. It is the first time for us to recognize a novel role of miR-27a in promoting myogenic tans-differentiation in HSCs. The finding also suggested similar bio-functions of the same miRNA in different types of tissues or cells. However, further effort is needed to determine the role of miR-27a in myogenic trans-differentiation of activated HSCs.

7. The biological significance of miR-27a regulated protein in HSCs

In order to validate the biological significance of miR-27a regulated proteins identified by cICAT proteomic strategy, the function of FHL1, one of the highest increased proteins which not only related to cell growth [28] but also played a crucial role in embryonic skeletal muscle myogenesis [32], was evaluated in miR-27a transfectants. Three different siRNA targeting FHL1 were compared. The one possessed the highest knockdown efficiency (Figure S2) was used in the following experiment. Our data showed that FHL1 involved in miR-27a related HSCs proliferation and migration, knockdown of FHL1 significantly inhibited the proliferation and migration of LX2/miR-27a transfectants (Figure 6). Interestingly, in a recent study based on 2-dimensional polyacrylamide gel electrophoresis (2D-PAGE) proteomic approach, FHL-1 was identified as one of the most prominently up-regulated proteins in pulmonary hypertension mouse model, and a similar effects of FHL-1 on promoting pulmonary arterial smooth muscle cell migration and proliferation has also been evidenced [35].
Figure 6

Involvement of FLH1 in miR-27a related HSCs proliferation and migration.

Knockdown of FLH1 suppressed cell proliferation in LX2/miR-27a transfectants. (A) EdU cell proliferation assay. EdU was detected by Apollo 567 fluorescent dye (red) and nuclei were counterstained with Hoechst 33342 (blue) (original magnification ×200). (B) Statistical results of three independent experiments. The results are expressed as the labeling index according to the following formula: number of EdU-positive nuclei x 100/number of total nuclei. FHL1 was required for increased migration in LX2/miR-27a transfectants. (C) Migration assays. LX2/miR-27a transfectants were plated on 8-lm pore size Transwell inserts for 16 hours. The number of migrated cells was counted manually (original magnification ×200). (D) The statistical results of three independent experiments. Each image is a representative of three independent experiments. ***P<0.001, **P<0.01 compared with LX2/miR-neg.

Involvement of FLH1 in miR-27a related HSCs proliferation and migration.

Knockdown of FLH1 suppressed cell proliferation in LX2/miR-27a transfectants. (A) EdU cell proliferation assay. EdU was detected by Apollo 567 fluorescent dye (red) and nuclei were counterstained with Hoechst 33342 (blue) (original magnification ×200). (B) Statistical results of three independent experiments. The results are expressed as the labeling index according to the following formula: number of EdU-positive nuclei x 100/number of total nuclei. FHL1 was required for increased migration in LX2/miR-27a transfectants. (C) Migration assays. LX2/miR-27a transfectants were plated on 8-lm pore size Transwell inserts for 16 hours. The number of migrated cells was counted manually (original magnification ×200). (D) The statistical results of three independent experiments. Each image is a representative of three independent experiments. ***P<0.001, **P<0.01 compared with LX2/miR-neg.

Conclusions

The data of present study indicated that miR-27a influenced the activation of HSCs by affecting several groups of proteins. These results not only explained our previous finding that over-expression of miR-27a promoted HSC activation with reduced cytoplasmic lipid drops and increased cell proliferation [8], but also revealed a novel role of miR-27a in promoting the myogenic trans-differentiation of activated HSC into myofibroblast. The pattern of miR-27a regulation on protein expression might well reflect the emerging picture of miRNA regulation in animals is far richer and more complex than the crisp linear pathways [1]. Our study also validated proteomic strategy as a promising tool for functional study of miRNA. In the future, it will be interesting to uncover the mechanisms underlying the regulation of miR-27a on these functionally related genes. Validation of myogenesis related genes found by cICAT proteomic analyses. The expression of TPM1, MYO9B and MYL9 encoding mRNA was evaluated by RT-PCR in LX2/miR-27a stable transfectants. *P<0.05, compared with LX2/miR-neg. (TIF) Click here for additional data file. Knockdown efficiency of FHL1 siRNA, LX2 cells were transfected with FHL1 specific siRNA or with NTC siRNA, after 48 hours, their mRNA levels were determined by quantitative polymerase chain reaction. GAPDH was used as housekeeping gene. NTC, non-targeting control siRNA transfected cells. **P<0.01 compared with NTC. (TIF) Click here for additional data file. Primer Sets for Real-time PCR. *Sense primers for mature miR-27a were provided here, anti-sense primer was provided by Invitrogen as Universal q-PCR Primer. (DOC) Click here for additional data file. Protein List of 2 Independent 2D nano-LC-MS/MS Analysis of LX2/miR-27a and LX2/miR-neg. (XLS) Click here for additional data file. List of Proteins Identified and Quantified in LX2/miR-27a and LX2/miR-neg. (XLS) Click here for additional data file. List of Proteins Up-or Down-regulated in LX2/miR-27a Compared with LX2/miR-neg. (XLS) Click here for additional data file.
  33 in total

Review 1.  Fibulins: a versatile family of extracellular matrix proteins.

Authors:  Rupert Timpl; Takako Sasaki; Günter Kostka; Mon-Li Chu
Journal:  Nat Rev Mol Cell Biol       Date:  2003-06       Impact factor: 94.444

2.  Growth-regulated recruitment of the essential yeast ribosomal protein gene activator Ifh1.

Authors:  Stephan B Schawalder; Mehdi Kabani; Isabelle Howald; Urmila Choudhury; Michel Werner; David Shore
Journal:  Nature       Date:  2004-12-23       Impact factor: 49.962

3.  Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2.

Authors:  Mario Acunzo; Giulia Romano; Dario Palmieri; Alessandro Laganá; Michela Garofalo; Veronica Balatti; Alessandra Drusco; Mario Chiariello; Patrick Nana-Sinkam; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

4.  Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis.

Authors:  L Xu; A Y Hui; E Albanis; M J Arthur; S M O'Byrne; W S Blaner; P Mukherjee; S L Friedman; F J Eng
Journal:  Gut       Date:  2005-01       Impact factor: 23.059

5.  Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation.

Authors:  C A Carlson; K H Kim
Journal:  J Biol Chem       Date:  1973-01-10       Impact factor: 5.157

Review 6.  Regulation of smooth muscle actin-myosin interaction and force by calponin.

Authors:  S J Winder; B G Allen; O Clément-Chomienne; M P Walsh
Journal:  Acta Physiol Scand       Date:  1998-12

7.  RhoA signaling via serum response factor plays an obligatory role in myogenic differentiation.

Authors:  L Wei; W Zhou; J D Croissant; F E Johansen; R Prywes; A Balasubramanyam; R J Schwartz
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157

8.  Muscle LIM protein, a novel essential regulator of myogenesis, promotes myogenic differentiation.

Authors:  S Arber; G Halder; P Caroni
Journal:  Cell       Date:  1994-10-21       Impact factor: 41.582

9.  Analysis of fibronectin receptor function with monoclonal antibodies: roles in cell adhesion, migration, matrix assembly, and cytoskeletal organization.

Authors:  S K Akiyama; S S Yamada; W T Chen; K M Yamada
Journal:  J Cell Biol       Date:  1989-08       Impact factor: 10.539

10.  The distribution of tenascin coincides with pathways of neural crest cell migration.

Authors:  E J Mackie; R P Tucker; W Halfter; R Chiquet-Ehrismann; H H Epperlein
Journal:  Development       Date:  1988-01       Impact factor: 6.868

View more
  5 in total

Review 1.  The miR-23-27-24 cluster: an emerging target in NAFLD pathogenesis.

Authors:  Lin Ru; Xiao-Mei Wang; Jun-Qi Niu
Journal:  Acta Pharmacol Sin       Date:  2021-12-10       Impact factor: 7.169

2.  Correction: Functional Study of miR-27a in Human Hepatic Stellate Cells by Proteomic Analysis: Comprehensive View and a Role in Myogenic Tans-Differentiation.

Authors: 
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

3.  MiR-27a-5p Increases Steer Fat Deposition Partly by Targeting Calcium-sensing Receptor (CASR).

Authors:  Wucai Yang; Keqiong Tang; Yaning Wang; Linsen Zan
Journal:  Sci Rep       Date:  2018-02-14       Impact factor: 4.379

4.  MiR-27a as a predictor for the activation of hepatic stellate cells and hepatitis B virus-induced liver cirrhosis.

Authors:  Hui Zhang; Xiu-Li Yan; Xin-Xin Guo; Miao-Juan Shi; Yi-Yu Lu; Qian-Mei Zhou; Qi-Long Chen; Yi-Yang Hu; Lie-Ming Xu; Shuang Huang; Shi-Bing Su
Journal:  Oncotarget       Date:  2017-12-15

5.  Crosstalk between Epigenetic Modulations in Valproic Acid Deactivated Hepatic Stellate Cells: An Integrated Protein and miRNA Profiling Study.

Authors:  Peng Lu; Min Yan; Li He; Jing Li; Yuhua Ji; Juling Ji
Journal:  Int J Biol Sci       Date:  2019-01-06       Impact factor: 6.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.